Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Esmethadone - Relmada Therapeutics

Drug Profile

Esmethadone - Relmada Therapeutics

Alternative Names: +-Methadone - Relmada Therapeutics; 6S-Methadone - Relmada Therapeutics; d Methadone - Relmada Therapeutics; Dextromethadone - Relmada Therapeutics; Esmethadone hydrochloride - Relmada Therapeutics; REL 1017; S-(+)-methadone; S-Methadone - Relmada Therapeutics

Latest Information Update: 11 Aug 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cornell University
  • Developer Relmada Therapeutics
  • Class Analgesics; Antidepressants; Antipsychotics; Drug withdrawal therapies; Eye disorder therapies; Ketones; Small molecules
  • Mechanism of Action NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Postherpetic neuralgia; Amyotrophic lateral sclerosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Major depressive disorder
  • Preclinical Eye disorders; Mitochondrial disorders; Rett syndrome
  • No development reported Neuropathic pain

Most Recent Events

  • 09 Aug 2022 Esmethadone - Relmada Therapeutics receives Fast Track designation for Major depressive disorder [PO,Tablet] (Monotherapy) in USA
  • 29 Apr 2022 Pharmacodynamics data from preclinical studies in Major depressive disorder was released by Relmada Therapeutics
  • 23 Feb 2022 Relmada Therpauetics announces intention to file NDA to US FDA for Major depressive disorder
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top